Ignyte Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $57.50M |
|---|---|
| IPO Date | Jan 28, 2021 |
| CEO | David I. Rosenberg; David J. Strupp, Jr. |
| Left Lead | EarlyBirdCapital |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 21 months |
| IPO Sector |
Healthcare
Life sciences, biotechnology and healthcare |
| IPO Geography | Global |
| Target Company | Peak Bio |
| Deal Announced | Apr 28, 2022 |
| Deal Size, $M | $205.38M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 25, 2022 |
| Amendment Vote | TBD |
| Closing Date | Nov 1, 2022 |
Formerly IGNY
PKBO
PKBOW
| Price | $0.02 |
|---|---|
| Last closing price | $0.02 |
| H/L, 52-week | $0.06 / $10.79 |
| Volume, today | 66,140 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Ignyte Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 27 filings and events
- 1 underwriters
- 4 deal advisors
- 3 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| David I. Rosenberg | 47 | Chairman of the Board and Co-Chief Executive Officer |
| David J. Strupp, Jr. | 52 | Co-Chief Executive Officer and Director |
| Steven Kaplan | 57 | Chief Financial Officer and Director |
| Cheryl Cohen | 54 | Director |
| Charles Wilson, Ph.D. | 56 | Director |
| John Andrew Boockvar, M.D. | 49 | Director |
| Richard J. Rosenstock | 69 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| EarlyBirdCapital | BR | 5,000,000 | units |
| 5,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| BCMA | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.